ADMA BIOLOGICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ADMA BIOLOGICS, INC. (ADMA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.96 per share for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2020-11-05
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $2.96, a 13.45% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $3.42, a 8.06% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $3.72, a 25.60% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $5.00, a 16.25% decline year-over-year.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $3.49, a 15.90% decline from fiscal 2018.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $4.15, a 11.26% increase from fiscal 2017.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $3.73, a 39.84% decline from fiscal 2016.
- ADMA BIOLOGICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $6.20, a 37.50% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2020-09-30 | $2.96 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $2.96 10-Q · filed 2020-08-05 | ||||
| 2020-03-31 | $2.96 10-Q · filed 2020-05-06 | ||||
| 2019-12-31 | $3.49 10-K · filed 2020-03-13 | ||||
| 2019-09-30 | $3.49 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $3.47 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $3.42 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $4.15 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | $3.99 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $3.87 10-Q · filed 2018-08-10 | ||||
| 2018-03-31 | $3.72 10-Q · filed 2018-05-14 | ||||
| 2017-12-31 | $3.73 10-K · filed 2019-03-13 | ||||
| 2017-09-30 | $3.76 10-Q · filed 2017-11-03 | ||||
| 2017-06-30 | $3.79 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | $5.00 10-Q · filed 2017-05-12 | ||||
| 2016-12-31 | $6.20 10-K · filed 2018-03-29 | ||||
| 2016-09-30 | $6.20 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $6.20 10-Q · filed 2016-08-12 | ||||
| 2016-03-31 | $5.97 10-Q · filed 2016-05-13 | ||||
| 2015-12-31 | $9.92 10-K · filed 2017-02-24 | ||||
| 2015-09-30 | $10.17 10-Q · filed 2015-11-10 | ||||
| 2015-06-30 | $10.46 10-Q · filed 2015-08-11 | ||||
| 2015-03-31 | $10.47 10-Q · filed 2015-05-12 | ||||
| 2014-12-31 | $8.50 10-K · filed 2016-03-23 | ||||
| 2014-09-30 | $8.50 10-Q · filed 2014-11-10 | ||||
| 2014-06-30 | $8.50 10-Q · filed 2014-08-11 | ||||
| 2013-12-31 | $7.56 10-K · filed 2015-03-09 | ||||
| 2013-09-30 | $7.56 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | $7.56 10-Q · filed 2013-08-12 | ||||
| 2013-03-31 | $7.56 10-Q · filed 2013-05-14 | ||||
| 2012-12-31 | $7.56 10-K · filed 2014-03-28 | $9.60 10-K · filed 2013-03-06 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |